Updated:
Tandem Diabetes Care Inc.
Tandem Diabetes Care, headquartered in San Diego, is a publicly traded medical-device company (NASDAQ: TNDM) that designs and sells insulin pumps and...
Tandem Diabetes Care Inc.
Tandem Diabetes Care, headquartered in San Diego, is a publicly traded medical-device company (NASDAQ: TNDM) that designs and sells insulin pumps and related software. The company was founded in 2006 by a team of engineers and clinicians; John Sheridan served as CEO through the public offering in 2013 and later through 2021. The underlying wealth of the firm is held by public shareholders—no single family controls a majority stake (per SEC filings, 2024). The company's two current pump platforms are the t:slim X2 and the Tandem Mobi. The t:slim X2 features a color touchscreen and supports both Dexcom G6 and Abbott FreeStyle Libre 3 Plus CGM integration. The Tandem Mobi is a smaller, wearable pump controllable via a smartphone app. Both systems run Control-IQ+ technology, which automatically adjusts basal insulin and delivers correction boluses. Tandem sells directly to patients in the United States and through distributors in Canada, the UK, Germany, and Australia. A 2023 study published in Diabetes Technology & Therapeutics reported improved time-in-range outcomes for users of the t:slim X2 with Control-IQ (per Beck RW et al., 2023). Tandem employs a direct sales and support model, with a 24/7 technical support team based in the US. The company does not disclose total professionals but reported 2,100 employees in its most recent annual filing (per Tandem 2023 10-K, February 2024). Revenue is generated from pump hardware sales and recurring consumables such as infusion sets and reservoirs. The company maintains a single corporate headquarters in San Diego and does not operate a separately branded family office or philanthropic arm. Tandem's structural differentiator is its focus on software-upgradeable hardware—the t:slim X2 can receive over-the-air algorithm updates, a feature rare in insulin pumps. This allows the company to improve clinical outcomes without requiring patients to buy a new device, a competitive advantage against closed-system rivals like Medtronic.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Sector focus
Frequently asked questions
Who leads product development at Tandem Diabetes Care?
Tandem's product development is overseen by its executive team under CEO John Sheridan (as of 2025, the CEO is John Sheridan, per the company's 2024 proxy statement). The R&D team includes engineers focused on hardware, embedded software, and algorithm design. The company does not publicly name a single chief medical officer or head of product.
How does Tandem's Control-IQ+ technology differ from Medtronic's SmartGuard?
Control-IQ+ uses a model-predictive control algorithm that adjusts basal insulin every five minutes based on CGM trends and also delivers automatic correction boluses when glucose is predicted to exceed 180 mg/dL. Medtronic's SmartGuard uses a simpler threshold-suspend approach. Clinical data from a 2023 study showed Tandem's system improved time-in-range by about 2.6 hours per day compared to a control group (per Beck RW et al., Diabetes Technology & Therapeutics, 2023).
Does Tandem operate any separate investment or family office entity?
No. Tandem Diabetes Care is a publicly traded corporation (TNDM) with no disclosed family office, venture arm, or investment subsidiary. Its capital structure consists of common equity held by institutional and retail shareholders.
What is Tandem's distribution model outside the United States?
Tandem sells directly in the US and through distributors in select international markets, including Canada, the UK, Germany, and Australia (per company 2023 Annual Report). The company also operates a subsidiary in Germany. It does not disclose distributor names or country-level revenue.
Has Tandem issued recalls or safety warnings for its pumps?
Yes. In 2022, Tandem issued an urgent medical device correction for the t:slim X2 regarding a potential occlusion alarm issue. In 2024, the FDA issued a Class I recall for certain Tandem Mobi pump charging cables due to fire risk (per FDA recall database, January 2024). No deaths were associated with either event.
Who are Tandem's primary competitors?
Tandem competes with Medtronic (MiniMed series), Insulet (Omnipod), and Roche (Accu-Chek) in the insulin pump market. It also faces competition from emerging startups such as EOFlow (now under Medtronic) and Beta Bionics (iLet pump). In the CGM space, Tandem partners with Dexcom and Abbott rather than competing.
What is the revenue mix between hardware and consumables for Tandem?
Tandem does not separately break out hardware versus consumables revenue in its financial filings. However, the company's 2023 10-K notes that pump shipments generate upfront revenue and recurring revenue from infusion sets, reservoirs, and CGM sensors sold through its channel. The majority of revenue in 2023 came from pump sales and supplies combined ($748M total revenue).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: